FLAG-Ida regimen

WikiDoc Resources for FLAG-Ida regimen
Articles
Most recent articles on FLAG-Ida regimen Most cited articles on FLAG-Ida regimen Review articles on FLAG-Ida regimen Articles on FLAG-Ida regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on FLAG-Ida regimen Images of FLAG-Ida regimen Photos of FLAG-Ida regimen Podcasts & MP3s on FLAG-Ida regimen Videos on FLAG-Ida regimen
Evidence Based Medicine
Cochrane Collaboration on FLAG-Ida regimen Bandolier on FLAG-Ida regimen TRIP on FLAG-Ida regimen
Clinical Trials
Ongoing Trials on FLAG-Ida regimen at Clinical Trials.gov Trial results on FLAG-Ida regimen Clinical Trials on FLAG-Ida regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on FLAG-Ida regimen NICE Guidance on FLAG-Ida regimen NHS PRODIGY Guidance FDA on FLAG-Ida regimen CDC on FLAG-Ida regimen
Books
Books on FLAG-Ida regimen
News
FLAG-Ida regimen in the news Be alerted to news on FLAG-Ida regimen News trends on FLAG-Ida regimen
Commentary
Blogs on FLAG-Ida regimen
Definitions
Definitions of FLAG-Ida regimen
Patient Resources / Community
Patient resources on FLAG-Ida regimen Discussion groups on FLAG-Ida regimen Patient Handouts on FLAG-Ida regimen Directions to Hospitals Treating FLAG-Ida regimen Risk calculators and risk factors for FLAG-Ida regimen
Healthcare Provider Resources
Symptoms of FLAG-Ida regimen Causes & Risk Factors for FLAG-Ida regimen Diagnostic studies for FLAG-Ida regimen Treatment of FLAG-Ida regimen
Continuing Medical Education (CME)
CME Programs on FLAG-Ida regimen
International
FLAG-Ida regimen en Espanol FLAG-Ida regimen en Francais
Business
FLAG-Ida regimen in the Marketplace Patents on FLAG-Ida regimen
Experimental / Informatics
List of terms related to FLAG-Ida regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: IDA-FLAG Regimen; Idarubicin-Fludarabine-AraC/G-CSF Regimen

Overview

FLAG-Ida regimen refers to idarubicin, fludarabine, high-dose cytarabine (AraC) and filgrastim (G-CSF), used as a remission-induction treatment for for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.

Regimen

IDAIdarubicin

FLFludarabine

ACytarabine (AraC)

GFilgrastim (G-CSF)

Indications

• Poor-risk myelodysplastic syndromes and acute myeloid leukaemia.